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Abstract 26 
Rationale: Zika virus (ZIKV) is a pathogenic virus known to cause a wide range of 27 
congenital abnormalities, including microcephaly, Guillain-Barre syndrome, 28 
meningoencephalitis, and other neurological complications, in humans. This study 29 
investigated the noninvasive detection of ZIKV infection in vivo, which is necessary 30 
for elucidating the virus’s mechanisms of viral replication and pathogenesis, as well as 31 
to accelerate the development of anti-ZIKV therapeutic strategies. 32 
Methods: In this study, a recombinant ZIKV harbouring Nluc gene (ZIKV-Nluc) was 33 
designed, recovered, and purified. The levels of bioluminescence were directly 34 
correlated with viral loads in vitro and in vivo. The dynamics of ZIKV infection in A129 35 
(interferon (IFN)-α/β receptor deficient), AG6 (IFN-α/β and IFN-γ receptor deficient), 36 
and C57BL/6 mice were characterized. Pregnant dams were infected with ZIKV-Nluc 37 
at E10 via intra footpad injection. Then, the pooled immune sera (anti-ZIKV 38 
neutralizing antibodies) #22-1 in ZIKV-Nluc virus-infected mice were visualized. 39 
Results: ZIKV-Nluc showed a high genetic stability and replicated well in cells with 40 
similar properties to the wild-type ZIKV (ZIKVwt). Striking bioluminescence signals 41 
were consistently observed in animal organs, including spleen, intestine, testis, 42 
uterus/ovary, and kidney. The ileocecal junction was found to be the crucial visceral 43 
target. Infection of pregnant dams with ZIKV-Nluc showed that ZIKV was capable of 44 
crossing the maternal-fetal barrier to infect the fetuses via vertical transmission. 45 
Furthermore, it was visualized that treatment with the pooled immune sera was found 46 
to greatly restrict the spread of the ZIKV-Nluc virus in mice. 47 
Conclusions: This study is the first to report the real-time noninvasive tracking of the 48 
progression of ZIKV invading immune-sheltered tissues and propagating vertically 49 
during pregnancy. The results demonstrate that ZIKV-Nluc represents a powerful tool 50 
for the study of the replication, dissemination, pathogenesis, and treatment of ZIKV in 51 
vitro and in vivo. 52 
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  56 
Introduction 57 
Zika virus (ZIKV) is a mosquito-borne virus that belongs to the Flaviviridae family [1]. 58 
ZIKV was first isolated in 1947 from a febrile rhesus macaque in the Zika forest of 59 
Uganda [2]. Only 14 cases of sporadic infection with mild symptoms were reported in 60 
the following 60 years [3-5]. After several epidemics in Yap Island in 2007 and in 61 
French Polynesia and other Pacific islands in 2013-2014, ZIKV colonised the Americas 62 
in February 2015, causing 707,133 cases of autochthonous infection within 48 countries 63 
and territories by late 2016 [3, 6, 7]. During these large epidemics in the Americas, 64 
ZIKV infection resulted in severe pathological complications, notably microcephaly in 65 
newborns and Guillain-Barré syndrome (GBS) in adults [4, 6, 8]. The virus is mainly 66 
transmitted by the bite of Aedes mosquitoes, but direct, interhuman transmission 67 
through sexual or vertical route has also been confirmed, setting ZIKV apart from most 68 
other flaviviruses [9]. To date, there is no licensed vaccine or antiviral therapy available 69 
for the treatment of ZIKV infection. The efficient transmission of this virus combined 70 
with deficient antiviral strategies has exacerbated public panic over ZIKV [10].  71 
The mechanisms for the dissemination and pathogenesis of ZIKV in developing 72 
fetuses, pregnant mothers, and adults remain largely unknown. ZIKV is likely to invade 73 
a unique set of immune-sheltered tissues, including the brain, testis, and placenta. 74 
Several ZIKV animal infection models have been previously established [11] to 75 
quantify viral genomes and antigens, which have provided useful information about 76 
both the viral and host factors that determine replication and pathogenesis [12-14]. 77 
However, it has not been possible to monitor the real-time patterns of ZIKV infection 78 
through these methods [13]. The collection of tissues and organs to evaluate ZIKV 79 
infection requires the euthanasia of the animals, and important tissues or organs may 80 
be missed if samples are not taken adequately [13, 14]. 81 
Bioluminescence imaging is a sensitive and non-invasive technology that allows 82 
for the visualization of viral dynamics in real time [15, 16]. This strategy measures the 83 
light generated by luciferase-catalysed oxidation reactions, an indicator of the extent of 84 
infected tissues, by using a charge-coupled device (CCD) camera [17]. 85 
Bioluminescence imaging measures the spatial and temporal progression of both 86 
primary infection and reinfection in the same animal model, which is able to not only 87 
reduce the inter-animal variability and animal suffering, but also improve the accuracy, 88 
stability, and reproducibility of the results [18, 19]. Bioluminescence imaging has been 89 
widely utilised in the study of viruses, including influenza virus, enterovirus 71, herpes 90 
simplex virus, respiratory syncytial virus, dengue virus, Japanese encephalitis virus, 91 
monkeypox virus, and hepatitis C virus [15-17, 19-23]. Recently, bioluminescence 92 
imaging assays of flaviviruses infection in mice have been implemented using 93 
recombinant viruses harbouring the firefly luciferase (Fluc) or Renilla luciferase (Rluc) 94 
gene [19, 20, 24]. Compared with Fluc and Rluc, the very small nanoluciferase (Nluc) 95 
(19-kDa) produces 150-fold more light [17, 25], and shows a greater potential for 96 
bioluminescence imaging [26]. To date, there have been no successful attempts at the 97 
non-invasive detection of ZIKV infection in vivo, which is warranted for characterizing 98 
the mechanisms of the replication and pathogenesis of the virus, as well as to improve 99 
the preclinical evaluation of vaccines, antiviral drugs, or therapeutic antibodies for 100 
ZIKV.  101 
In this study, a recombinant ZIKV harbouring the Nluc gene (ZIKV-Nluc) was 102 
designed, recovered, and purified. This recombinant virus showed a high genetic 103 
stability and replicated well in cells with similar properties to the wild-type ZIKV 104 
(ZIKVwt). The levels of bioluminescence were found to be directly correlated with 105 
viral loads in vitro and in vivo. The dynamics of ZIKV infection in A129 (interferon 106 
(IFN)-α/β receptor deficient), AG6 (IFN-α/β and IFN-γ receptor deficient), and 107 
C57BL/6 mice were well characterized. To our knowledge, this is the first real-time 108 
non-invasive tracking of the progression of ZIKV invading immune-sheltered tissues, 109 
as well as its vertical propagating, during pregnancy. The results presented in this study 110 
demonstrate that ZIKV-Nluc is a powerful tool for use in the study of the replication, 111 
dissemination, and pathogenesis of ZIKV in vitro and in vivo. 112 
 113 
Results 114 
Generation and characterization of a stable reporter ZIKV  115 
To generate a bioluminescent ZIKV reporter virus, a Nluc gene was engineered into a 116 
full-length infectious cDNA clone of an Asian-lineage Zika virus, SZ-WIV01 [10]. As 117 
shown in Figure 1A, the monomeric Nluc gene flanked by the N-terminal 38 amino 118 
acids of C protein (C38) and a FMDV2A (F2A) sequence was inserted between 5’UTR 119 
and the N-terminus of open reading frame (ORF). The C38 sequence was required for 120 
maintaining genome cyclization and for viral RNA replication. The F2A sequence was 121 
placed downstream of the Nluc gene to ensure that the Nluc protein was properly 122 
processed [19, 27].  123 
P0 ZIKV-Nluc virus was rescued through the transfection of Vero cells with the 124 
full-length ZIKV-Nluc cDNA clone (ZIKV-Nluc-FL). P0 ZIKV-Nluc virus harbouring 125 
the intact genome, without the loss of Nluc, was confirmed by RT-PCR assay by 126 
amplifying the fragment from 5’UTR to the C gene (Figure 1B). Compared with 127 
ZIKVwt, the P0 ZIKV-Nluc virus produced smaller plaques, which were visualized by 128 
immunostaining (P < 0.001) (Figure 1C) and 0.33% neutral red (P < 0.001) (Figure 1D), 129 
demonstrating that the insertion of the Nluc gene attenuated the virus in cell culture. 130 
The infection of Vero cells with P0 virus resulted in the robust production of luciferase 131 
activity (Figure 1E), despite the P0 virus having lower infectious titres, at 3 and 4 days 132 
post infection (dpi) (P < 0.05), and exhibiting a lower replication efficiency than 133 
ZIKVwt (Figure 1F).    134 
The genetic stability of ZIKV-Nluc is prerequisite for its use. To test the stability 135 
of the ZIKV-Nluc virus, the P0 ZIKV-Nluc virus was passaged in Vero cells for five 136 
rounds. After each passage (P1 to P5), the viruses were examined for the Nluc gene. 137 
The RT-PCR results indicated that the Nluc gene began to be lost in the P1 viral stock 138 
(Figure 1G). To improve the stability of ZIKV-Nluc, the P0 ZIKV-Nluc virus was 139 
purified for four rounds in Vero cells using a double plaque assay (Figure 1H). The 140 
resulting P8 ZIKV-Nluc virus was re-passaged five times in Vero cells, the passages of 141 
which did not result in any apparent loss of NLuc gene, indicating that the genome of 142 
ZIKV-Nluc was stable for at least five life cycles (Figure 1I). Sequence analysis of the 143 
entire genome of P8 ZIKV-Nluc virus revealed no nucleotide substitution (Fasta data-144 
S1).   145 
 146 
 147 
Figure 1. Generation and characterization of ZIKV-Nluc. (A) Strategy for constructing the full-148 
length cDNA clone of ZIKV-Nluc. The monomeric Nluc gene flanked by the N-terminal 38 amino 149 
acids of C protein (C38) and a FMDV2A (F2A) sequence was inserted between 5’UTR and the C 150 
gene. (B) The stability of the P0 ZIKV-Nluc virus. Viral RNAs were extracted from the supernatants, 151 
and RT-PCR was performed with a pair of primers surrounding the Nluc-2A fragment. (C) The 152 
plaque morphology of the P0 ZIKV-Nluc virus in Vero cells, visualized by immunostaining 153 
following incubation for 4 days. (D) The plaque morphology of the P0 ZIKV-Nluc virus in Vero 154 
cells, visualized using 0.33% neutral red following incubation for 5 days. (C, D) The average sizes 155 
of viral plaques (mean ± standard deviation) were quantified by counting all of the intact plaques. 156 
(E) Nluc activities of the infected Vero lysates by P0 ZIKV-Nluc virus at different times post 157 
infection at low multiplicity of infection (MOI) of 0.01. (F) Growth curves of P0 ZIKV-Nluc virus 158 
determined by an immunostaining plaque assay at an MOI of 0.01. (G) ZIKV-Nluc stability during 159 
virus passaging. Total RNA was extracted from the cells infected by each passaged virus, and RT-160 
PCR was performed with a pair of primers surrounding the Nluc-2A fragment. (H) Schematic of 161 
plaque purification. (I) ZIKV-Nluc stability following plaque purification.    162 
 163 
To further validate the ZIKV-Nluc virus (P8), viral protein synthesis was 164 
examined in Vero cells. As measured by IFA assays, the amount of E-positive cells 165 
infected with ZIKV-Nluc virus increased with the time of infection, although the 166 
percentage of positive cells was less than that of ZIKVwt before the peak at 3 dpi 167 
(Figure 2A). Next, we determined the kinetics of the luciferase activities in Vero cells 168 
infected with different MOIs (0.001, 0.01, 0.1 or 1) of ZIKV-Nluc virus. As shown in 169 
Figure 2B, the growth of the Nluc signal showed a good correlation with the MOI in 170 
the ZIKV-Nluc virus (P8)-infected Vero cells. In a parallel experiment of double plaque 171 
assay, P8 ZIKV-Nluc virus showed low infectious titres at 2, 3, 4, and 5 dpi (P < 0.05). 172 
However, the growth pattern for the bioluminescent virus was similar to that for 173 
ZIKVwt (Figure 2C). In addition, the MOI of 0.01 was selected and applied in 174 
subsequent correlation analyses of viral titres and Nluc activities. We demonstrated that 175 
there was an excellent linear correlation (r2 = 0.9114) between the Nluc signal values 176 
and the viral titres of P8 ZIKV-Nluc virus (Figure 2D). Collectively, the P8 ZIKV-Nluc 177 
virus showed a superior genetic stability and produced levels of luciferase activity that 178 
accurately reflected the replication of the virus in vitro. Therefore, this virus was used 179 
in further experiments.    180 
 181 
 182 
Figure 2. Replication of ZIKV-Nluc in cell culture. (A) IFA of E protein expression in Vero cells 183 
infected with the purified ZIKV-Nluc virus at an MOI of 0.05. (B) Nluc activities of infected Vero 184 
lysates by the purified ZIKV-Nluc virus at different times post infection at an MOI of 0.001, 0.01, 185 
0.1, and 1, respectively. (C) Growth curves of the purified ZIKV-Nluc virus determined by 186 
immunostaining plaque assay at an MOI of 0.01. (D) Linear correlation between viral titres and 187 
Nluc signal values of the purified ZIKV-Nluc virus in vitro. 188 
 189 
Pathogenicity of ZIKV-Nluc in A129, AG6, and C57BL/6 mice 190 
To determine whether the ZIKV-Nluc virus causes a similar disease progression 191 
compared to ZIKVwt, mice were infected with 1.2 × 105 IFU ZIKV-Nluc/ZIKVwt via 192 
the intraperitoneal (i.p.) route and monitored for 20 days for weight loss and mortality. 193 
Both A129 mice and AG6 mice infected with ZIKVwt showed weight loss starting at 4 194 
dpi, and all mice died between 7 and 9 dpi (Figures 3A and B). By contrast, in the ZIKV-195 
Nluc virus-infected mice, only 33.3% A129 mice and 50% AG6 showed significant 196 
weight loss and succumbed to infection by 19 and 18 dpi, respectively (Figures 3A and 197 
B). The immunocompetent mice, C57BL/6 mice, were not susceptible to infection with 198 
neither ZIKVwt nor ZIKV-Nluc (Figures 3A and B). The viral titres in sera obtained 199 
from A129 mice at 3 and 5 dpi were measured using an immunostaining focus assay 200 
(Figures 3C and D). A129 mice infected with ZIKV-Nluc were found to have significant 201 
different viral titres at both 3 dpi (P < 0.05) and 5 dpi (P < 0.01) compared to A129 mice 202 
infected with ZIKVwt (Figures 3C and D). These results showed that despite reduced 203 
levels of attenuation, the ZIKV-Nluc virus could develop detectable viral titres in sera, 204 
suggesting that the virus replicated well in immunodeficiency mouse models. In 205 
addition, C57BL/6 mice showed no clinical signs of disease or weight loss when 206 
infected with both ZIKV-Nluc and ZIKVwt. 207 
 208 
 209 
Figure 3. Pathogenicity of ZIKV-Nluc in A129, AG6, and C57BL/6 mice. (A, B) Groups of 210 
A129, AG6, and C57BL/6 mice (3-4 weeks old; n = 6) were infected intraperitoneally with 1.2 × 211 
105 IFU of WT or ZIKV-Nluc. Body weight loss and survival were monitored on a daily basis for 212 
20 days. (C, D) Two groups of A129 mice (3-4 weeks old; n = 3) were infected intraperitoneally 213 
with 1 × 104 IFU of WT or ZIKV-Nluc. Serum viral loads were determined at day 3 and day 5 by 214 
an immunostaining plaque assay. Data represent the mean ± SD analysed by Student’s t-test (two 215 
tailed) (*, P < 0.05; **, P < 0.01). 216 
 217 
Using ZIKV-Nluc for the bioluminescence imaging of ZIKV infection  218 
To investigate whether ZIKV-Nluc can be used as a tool for the bioluminescence 219 
imaging of ZIKV infection, A129 mice were inoculated with 1.2 × 105 IFU ZIKV-Nluc 220 
via the i.p. route, and the bioluminescent signal was monitored at regular times post 221 
infection. As shown in Figures 4A and B, a rapid dissemination of bioluminescence 222 
from the injection site was observed in A129 mice as early as at 1 dpi, with the peak 223 
bioluminescence occurring at 5 dpi (a robust bioluminescence signal was detected in 224 
the whole abdomen, brain, limbs, and tail). For some C57BL/6 mice, a slight detectable 225 
luminance signal above background was observed at the indicated time points (Figures 226 
4A and B). In a separate experiment, A129 mice were inoculated intracranially (i.c.) 227 
with 6 × 103 IFU ZIKV-Nluc, and the bioluminescence in the brain regions were 228 
monitored at 2, 4, and 5 dpi. The titres of ZIKV-Nluc were measured using the double 229 
plaque assay. A direct correlation (r2 = 0.9617) was found between the viral titres of 230 
ZIKV-Nluc and the intensity of luminescence, indicating that the virus replication in 231 
vivo could be reflected by the changes in luminescence intensity (Figures 4C and D). 232 
To further validate the correlations between the bioluminescent signals and viral loads, 233 
AG6 mice were inoculated with 6 × 104 IFU ZIKV-Nluc via the footpads. Tissues, 234 
including spleen, kidney, testis, and ileocecal junction, were isolated at 1, 3, and 5 dpi 235 
and subjected to bioluminescence imaging and viral load measurement. Linear 236 
regression analysis showed that Nluc signal values correlated well with viral RNA 237 
copies in mouse tissues (Figure S1). Collectively, using ZIKV-Nluc, the whole disease 238 
progression of the viral infection could be traced well via the IVIS CCD camera system.  239 
 240 
 241 
Figure 4. In vivo luminescence of ZIKV-Nluc-infected mice. (A, B) Groups of A129 and 242 
C57BL/6 mice (3-4 weeks old; n = 6) were infected intraperitoneally with 1.2 × 105 IFU of WT or 243 
ZIKV-Nluc. (A) Bioluminescence imaging of ZIKV-Nluc-infected mice was performed at the 244 
indicated times. Representative ventral views of the results were shown. (B) The average radiance 245 
of ZIKV-Nluc-infected mice was determined from region of interest (ROI) analysis of the ventral 246 
side. (C, D) Groups of AG6 mice (3-4 weeks old; n = 6) were infected with 6×103 IFU of ZIKV-247 
Nluc via the i.c. route. (C) Bioluminescence imaging of ROI from ZIKV-Nluc-infected mice was 248 
performed at the indicated times. (D) Linear correlation between the viral titres and Nluc signal 249 
values of the ZIKV-Nluc virus in vivo. 250 
 251 
Involvement of type I and type II IFN in viral dissemination 252 
To determine the mechanisms of ZIKV dissemination and pathogenesis in adults, 253 
pregnant mothers, and developing fetuses, the infection of mouse models by mimicking 254 
the natural infection route (footpad) is key [13, 28, 29]. A129, AG6, and C57BL/6 mice 255 
were infected with 6 × 104 IFU ZIKV-Nluc, or the parental ZIKV as control, via intra-256 
footpad injections. The resulting bioluminescent signal was monitored longitudinally 257 
at regular time points post infection. No real or effective bioluminescence was detected 258 
in the mock-infected AG6, A129, and C57BL/6 mice, nor in mice infected with ZIKV-259 
Nluc at 0 dpi (Figure S2). As shown in Figure 5 and Figure 6, in the infected A129 and 260 
AG6 mice, following the footpad injection, the bioluminescent signals were primarily 261 
observed at the local sites of inoculation and the peritoneal cavity at 1 dpi, further 262 
disseminating to the brain and other tissues or organs, peaking in the peritoneal cavity 263 
and brain at 5 dpi, and subsequently decreasing throughout the process of viral infection. 264 
These results revealed the complete process of ZIKV dissemination and showed that 265 
the ZIKV-Nluc virus primarily invaded various abdominal organs and the brain.   266 
 267 
 268 
Figure 5. Spatial and temporal progression of ZIKV-Nluc in AG6 and A129 mice in ventral 269 
views. Groups of AG6 (A) and A129 (B) mice (3-4 weeks old; n = 6) were infected with 6 × 104 270 
IFU of WT or ZIKV-Nluc via the footpad. The viral spread of ZIKV-Nluc-infected mice was 271 
monitored in real time at the indicated times. 272 
 273 
At 9 dpi, only a slight bioluminescent signal was detected in the peritoneal cavity 274 
in the majority of the A129 and AG6 mice. However, at 14 dpi, the real and effective 275 
bioluminescence was still detectable in the peritoneal cavity of both AG6 and A129 276 
mice (Figure 5 and Figure 6), highlighting the viscerotropism of ZIKV in vivo. By 277 
contrast, only a weak bioluminescent signal was detected in the peritoneal cavity of 278 
some C57BL/6 mice almost throughout the trial period. Next, we calculated the total 279 
flux of each ZIKV-Nluc-infected mouse, and found that the signal values of the AG6 280 
mice were significantly higher than those of the A129 mice at 2 dpi for the dorsal side 281 
(P < 0.05), and at 2 and 3 dpi for the ventral side (P < 0.05) (Figures 7A and B). These 282 
results indicated that although type I IFNs were crucial for the viscera dissemination of 283 
ZIKV-Nluc, type II IFN also played a role in the process by delaying disease 284 
development in the early stages of virus infection. 285 
 286 
 287 
Figure 6. Spatial and temporal progression of ZIKV-Nluc in AG6 and A129 mice in dorsal 288 
views. Groups of AG6 (A) and A129 (B) mice (3-4 weeks old; n = 6) were infected with 6 × 104 289 
IFU of WT or ZIKV-Nluc via the footpad. The viral spread of ZIKV-Nluc-infected mice was 290 
monitored in real time at the indicated times.  291 
 292 
 293 
Figure 7. Comparison of total fluxes from AG6 and A129 mice infected with ZIKV-Nluc. (A) 294 
The average radiance of AG6 and A129 mice infected with ZIKV-Nluc (mice in Figure 5 and Figure 295 
6) was determined by the ROI analysis of the ventral side. (B) The average radiance of AG6 and 296 
A129 mice infected with ZIKV-Nluc (Figure 5 and Figure 6) was determined by the ROI analysis 297 
of the dorsal side. Data represent the mean ± SD analysed by Student’s t-test (two tailed) (*, P < 298 
0.05; **, P < 0.01).  299 
 300 
Tissue localization of ZIKV-Nluc  301 
To accurately identify the potential target organs of ZIKV-Nluc in infected mice, the in 302 
vitro imaging of organs harvested from AG6, A129, and C57BL/6 mice infected with 303 
ZIKV-Nluc at 3 and 5 dpi was performed in a separate experiment. Marked Nluc signals 304 
were consistently observed in the abdominal organs of the infected AG6 and A129 mice, 305 
including in the spleen, intestine (i.e. ileocecal junction, a key region of the intestine), 306 
testis, uterus/ovary, and kidney at both time points (Figures 8A and B). Among these 307 
organs, the lymphoid rich organs, namely the spleen and the ileocecal junction, radiated 308 
two of the strongest light emissions, followed by the uterus/ovary, testis, and kidney. 309 
Bioluminescent signals in other organs, such as the brain, heart, and lung, varied 310 
individually among mice. For C57BL/6 mice, although only weak luciferase signals 311 
were detected in the intestines, no detectable bioluminescence was observed in other 312 
organs (Figures 8A and B). In addition, immunohistochemistry (IHC) staining of 313 
ileocecal junction, testis, and brain tissue sections showed a relatively clear distribution 314 
of E protein in AG6 mice infected with the ZIKV-Nluc virus (Figures 8C and D). By 315 
comparison, for C57BL/6 mice, the distribution of E protein was only found in ileocecal 316 
junction section at 5dpi (Figure S3). Although the possibility that infection in other 317 
anatomical tissues may have occurred at earlier time points, or infected cells may have 318 
migrated from one location to another at later time points, these results supported 319 
previous observations that ZIKV preferentially replicated in both male and female 320 
reproductive tracts and led to infertility in mice [12, 30]. 321 
 322 
 323 
Figure 8. Tissue localization of ZIKV-Nluc. Groups of A129, AG6 and C57BL/6 mice (3-4 weeks 324 
old; n = 6) were infected with 6 ×104 IFU of WT or ZIKV-Nluc via footpad. Immediately after 325 
bioluminescence imaging, ZIKV-Nluc-infected mice were sacrificed, and isolated organs including 326 
heart (H), liver (L1), spleen (S), lung (L2), kidney (K), uterus/ovary (U), testis (T), and brain (B) 327 
were subjected to in vitro bioluminescence imaging at 3 dpi (A) and 5 dpi (B). The expressions of 328 
E protein in ileocecal junction, testis and brainstem sections from infected AG6 mice were stained 329 
by immunohistochemistry at 3 dpi (C) and 5 dpi (D). Scale bars are 100 μm for lower magnification 330 
images (× 20) and boxes in lower magnification images indicated where the higher magnification 331 
images (× 80) were taken.   332 
 333 
Vertical transmission of ZIKV-Nluc    334 
Given the fact that embryonic day 10-13 (E10-13, later in gestation) corresponds to the 335 
period of neurogenesis in mice [1, 31, 32], we infected pregnant dams with 6 × 104 IFU 336 
ZIKV-Nluc at E10 via intra-footpad injection to determine the transmission of ZIKV 337 
from mother to offspring in mice. As shown in Figure 9A, in infected pregnant AG6 338 
mice, the bioluminescent signals were primarily detected at the local site of inoculation 339 
and in the peritoneal cavity at 1 dpi, which then disseminated to other organs before 340 
peaking at 5 dpi, decreasing steadily until delivery. By comparison, only a slight 341 
bioluminescence signal was detected in the brains of infected pregnant AG6 mice at 3 342 
and 5 dpi, which was markedly different from that of 3-week-old AG6 mice infected 343 
with ZIKV-Nluc. The peritoneal cavity of the maternal mice still radiated slight light 344 
emissions at 1 day postpartum. In terms of the newborn mice, 25 μl of diluted substrate 345 
via a single i.p. injection resulted in an exact and effective bioluminescence (Figure 9B), 346 
indicating that ZIKV was capable of crossing the maternal-fetal barrier to infect the 347 
fetuses through vertical transmission.  348 
 349 
 350 
Figure 9. Spatio-temporal dynamics of ZIKV-Nluc invading pregnant mice and spreading 351 
vertically to the fetuses. Four-week-old AG6 female mice (n = 3) were mated with AG6 males. On 352 
E10, pregnant mice were infected with 6 × 104 IFU of WT or ZIKV-Nluc via the footpad. Viral 353 
spreads from the ventral and dorsal views of ZIKV-Nluc-infected pregnant mice were monitored in 354 
real time at the indicated times (A). Bioluminescence imaging of fetuses from ZIKV-Nluc-infected 355 
dams was performed at day 1 after birth (B). 356 
 357 
Visualizing immunological protections of pooled immune serum  358 
Although pooled immune sera (neutralizing anti-ZIKV antibodies) were recommended 359 
for protection against ZIKV infection [28, 33], it is unclear how these sera suppress the 360 
progression of viral infection in vivo. We adopted our established bioluminescence 361 
imaging to evaluate the immunological effect of a pooled immune serum, #22-1, which 362 
conferred robust neutralizing activities against ZIKVwt (NT50 titre of ~2048). Firstly, 363 
80 IFU of the ZIKV-Nluc virus was pre-incubated with a 1:10 dilution of #22-1 at room 364 
temperature (RT) for 1.5 h before injection. The bioluminescent signal was monitored 365 
at regular time points post infection (Figure 10A). Pre-incubation with #22-1 366 
significantly reduced the bioluminescence signal at 3 and 5 dpi (Figures 10B and C), 367 
and the bioluminescence of the #22-1-treated mice peaked in the peritoneal cavity and 368 
brain at 7 dpi (Figure 10B and Figure S4A). By contrast, the bioluminescence of the 369 
control mice peaked in the peritoneal cavity and brain at 5 dpi, before decreasing along 370 
with the process of viral infection (Figure 10B and Figure S4A).   371 
Next, we designed a treatment regime of #22-1, as shown in Figure 10D. The 372 
pooled immune sera were administered at the indicated time points before and after 373 
infection with ZIKV-Nluc, while the bioluminescent signal was monitored at regular 374 
time points post infection. In the mice receiving PBS-immunized sera, a similar kinetic 375 
pattern of ZIKV-Nluc expression was observed in different tissues, with 376 
bioluminescence peaking at 5 dpi (Figure 10E and Figure S4B). Treatment with nine 377 
doses of #22-1 dramatically reduced the bioluminescent signal in almost all of the 378 
infected mice (Figures 10E and F, and Figure S4B). Taken together, the #22-1 treatment 379 
greatly restricted the spread of viral infection in vivo, which clearly demonstrated that 380 
the ZIKV-Nluc virus could be used as a tool for the real-time monitoring of how pooled 381 
immune sera (neutralizing anti-ZIKV antibodies or antiviral compounds) suppress the 382 
progression of viral infection.  383 
 384 
Figure 10. Application of ZIKV-Nluc for immunological protection evaluation. (A) 385 
Schematic representation of bioluminescence imaging of 3-4 weeks old AG6 mice receiving a 386 
mixture of ZIKV-Nluc and pooled immune serum, #22-1. (B) The viral spread from the ventral 387 
view of ZIKV-Nluc-infected mice was monitored in real time at the indicated times. (C) The 388 
average radiance of ZIKV-Nluc-infected mice was determined by ROI analysis of the ventral 389 
side. (D) Bioluminescence imaging of 3-4-week-old AG6 mice that received nine doses of #22-390 
1. (E) The viral spread from the ventral view of ZIKV-Nluc-infected mice was monitored in 391 
real time at the indicated times. (F) The average radiance of ZIKV-Nluc-infected mice was 392 
determined by ROI analysis of the ventral side. Data represent the mean ± SD analysed by 393 
Student’s t-test (two tailed) (*, P < 0.05; **, P < 0.01). 394 
 395 
Discussion 396 
ZIKV is a pathogenic virus that causes microcephaly, diffuse calcifications, GBS, 397 
meningoencephalitis, and other neurological complications in humans [4, 8, 34]. In this 398 
study, we generated a replication-competent Nluc reporter ZIKV, which is genetically 399 
stable in vitro and in vivo, which represents a powerful tool for the monitoring of the 400 
spatio-temporal dynamics of viral infection in living mice. For the first time, we report 401 
on the complete process of ZIKV dissemination, as well as the identification of the 402 
ileocecal junction as a crucial visceral target of viral infection, the tracking of the 403 
vertical propagation of ZIKV, and the congenital infection of fetuses during pregnancy. 404 
Our findings confirmed the utility of the reporter virus for use in immunological 405 
protection or therapeutic efficacy studies using mouse models. 406 
In the generated ZIKV-Nluc virus, the Nluc reporter was expressed as an 407 
additional part of the viral polyprotein, followed by its cleavage from the capsid protein 408 
mediated by 2A protease. Notably, C38, which retained the 5’ sequence downstream of 409 
the AUG region (5’DAR), the hairpin in the C protein-coding region (cHP), the 410 
5’cyclization sequence (5’CS), and the sequence downstream of the 5’CS-pseudoknot 411 
(DCS-PK) [35-37], was duplicated upstream of the reporter gene to ensure viral RNA 412 
replication. Similar strategies have been applied in previous studies to generate several 413 
flaviviruses carrying reporter genes [27, 38-41]. A major hurdle in the practical 414 
application of these reporter flaviviruses is the relative instability of viral genomes. It 415 
has been proposed that engineered viruses evolve during their lifetime, and that a stable 416 
reporter virus could be harvested by picking small plaques [27]. In our study, a strain 417 
of P8 ZIKV-Nluc virus was found to be stable after five rounds of viral infection with 418 
no nucleotide substitution in the genome. We postulated that the high stability of P8 419 
ZIKV-Nluc was due to the very small Nluc gene (513bp), the P0 stocks as a population 420 
(quasispecies) of general consensus sequence might contain few viral particles with 421 
mutant genomes, after purification, the single virus yields exhibited homogeneous 422 
entity and high genetic stability. Further studies are still warranted to investigate the 423 
reason for the high stability of ZIKV-Nluc. Heterologous gene insertions normally 424 
result in the attenuation of the constructed viruses both in vitro and in vivo [17, 19, 24, 425 
41-43]. As expected, the purified ZIKV-Nluc exhibited a lower replication kinetic in 426 
the cell culture and a relatively low pathogenicity in mice. Despite this, the ZIKV-Nluc 427 
virus showed a similar growth pattern compared to that of its parental counterpart and 428 
produced robust luciferase activities with a peak value of > 2 × 108 light units. The 429 
magnitude of the bioluminescence generated by ZIKV-Nluc correlated well with its 430 
titre in both the cell culture and mice, which was in agreement with the findings reported 431 
by studies on JEV and DENV reporter viruses [19, 24]. Such properties of ZIKV-Nluc 432 
provide a powerful means for further characterizing ZIKV dissemination in living mice 433 
using bioluminescence imaging.  434 
Using the ZIKV-Nluc virus, we visualized the real-time ZIKV infection in A129, 435 
AG6, and C57BL/6 mice. ZIKV is known to directly infect neuronal progenitor cells 436 
and causes microcephaly, among other severe pathological complications [44-46]. Here, 437 
we demonstrated that ZIKV-Nluc primarily spread to the peritoneal cavity in A129, 438 
AG6, and C57BL/6 mice at 1 dpi, and was sustained throughout the remaining infection 439 
course. We hypothesized that the high viral loads in the peritoneal cavity may 440 
contribute to the quick dissemination of ZIKV to the brain and other organs. Although 441 
ZIKV-Nluc was found to be confined to specific parts of the peritoneal cavity in 442 
immunocompetent C57BL/6 mice, the lack of type I IFN receptors in A129 mice is 443 
likely to have contributed to the rapid proliferation of the virus, as well as to its spread 444 
to the brain and other organs, which was consistent with a previous biochemical 445 
analysis that found that ZIKV did not antagonize type I IFN response by promoting the 446 
degradation of STAT2 and did not induce disease in immunocompetent mice [47]. By 447 
studying genetically deficient animals, previous studies have demonstrated that type I 448 
IFNs are crucial for the dissemination of JEV to visceral organs [19]. Type I IFNs serve 449 
as one of the key components in the innate immune system, and many interferon 450 
stimulated genes were found to be essential for viral restriction and clearance [48, 49]. 451 
After infection with a neurotropic virus, such as West Nile virus, the induction of type 452 
I IFN expression in the endothelium has been found to enhance tight junction integrity 453 
and limit the permeability of the blood‒brain barrier [17, 48, 50]. We also investigated 454 
the function of type II IFNs in the control of ZIKV infection. Compared with the singly-455 
deficient A129 mice, AG6 mice lacking both type I and type II IFN receptors were 456 
found to be more susceptible to ZIKV-Nluc, with significantly higher bioluminescent 457 
signals being observed at 2 dpi for the dorsal side and at 2 and 3 dpi for the ventral side, 458 
indicating that type II IFNs contribute to limiting systemic ZIKV infection in mice in 459 
the early stage. Neurons in the central nervous system (CNS) have a limited 460 
regeneration ability, implying that the noncytolytic clearance of virus from neuronal 461 
cells, rather than direct neuronal lysis, is required to maximize the preservation of CNS 462 
function [51]. Type II IFNs were previously found to non-cytolytically clear Sindbis 463 
virus and measles virus from infected CNS neurons [52, 53]. However, the protection 464 
of the noncytolytic immune response against neurotropic flavivirus has been disputed 465 
[51, 54]. Given that type II IFNs interact with type I IFNs through distinct as well as 466 
common IFN receptor complexes [55], we proposed that both type I and type II IFNs 467 
are functionally non-redundant for the anti-ZIKV defence, and may modulate virus 468 
dissemination by restricting infection in extraneural tissues before irreversible CNS 469 
damage in mice. Further studies will be needed to determine the exact mechanism of 470 
the non-cytolytic clearance of ZIKV from infected neurons in the CNS. 471 
ZIKV is known to preferentially replicate in the reproductive tract, including in 472 
the testis, uterus, and ovary [12, 30], and this has been was confirmed by the 473 
bioluminescence imaging of specific organs. However, whether the intestine is a 474 
potential target organ of ZIKV infection remains to be further clarified. In this study, 475 
we found that the Nluc signal was widespread in the whole intestine in all of the 476 
immunodeficient mice tested, indicating that the intestine is likely to serve as an 477 
important organ of ZIKV infection. Previously, luciferase signals were also detected in 478 
the intestine of singly-deficient A129 mice infected with JEV-Rluc or doubly-deficient 479 
AG129 mice infected with DENV-Fluc, suggesting that JEV and DENV can replicate 480 
in gut-associated lymphoid tissues [19, 24]. Nevertheless, it remains unclear which 481 
intestine segment is the exact ROI prone to viral infection. In this study, we excised the 482 
whole intestine of infected mice, and found that the anatomical location radiating the 483 
strongest light emission was the ileocecal junction. The ileocecal junction functions as 484 
a mechanical barrier against colonic reflux, and is involved in the “ileal brake”, which 485 
slows the transit of chyme through the intestinal tract [56, 57]. The fact that ZIKV 486 
targets the ileocecal junction is consistent with a recent study that found that the 487 
infection of enteric neurons with neurotropic flaviviruses causes delayed 488 
gastrointestinal transit in mice [58].  489 
Our study elucidated the spatio-temporal dynamics of ZIKV in pregnant mice and 490 
its subsequent vertical spread to the fetuses. The placenta develops within days of 491 
conception and acts as an innate barrier to invading microorganisms [59, 60]. Based on 492 
epidemiological data combined with the detection of proteins and nucleic acids, it has 493 
been previously suggested that ZIKV can cross the placental barrier, being directly 494 
associated with fetal death, microcephaly, and other fetal abnormalities during 495 
pregnancy [1, 61]. However, the mechanism for the infection and dissemination of 496 
ZIKV at the different stages of gestation remains unknown. In this study, by infecting 497 
pregnant AG6 mice with ZIKV-Nluc, the virus was found to primarily target the local 498 
site of inoculation and peritoneal cavity, subsequently spreading to other organs. The 499 
fetus may be highly sensitive to ZIKV infection during the first trimester of pregnancy 500 
[62]. However, devastating fetal outcomes, such as microcephaly, cerebral atrophy, 501 
ventricular enlargement, and cerebral calcifications, have also been found at other 502 
various gestational ages [59, 61]. Our results clearly demonstrated that the virus crossed 503 
the maternal-fetal barrier and infected newborn pups when the pregnant AG6 mice were 504 
infected at E10, corresponding to the period of neurogenesis in mice [1, 31]. Further 505 
longitudinal studies are needed in order to define the relationship between the severity 506 
of maternal infection and fetal consequences, as well as to determine the mechanism by 507 
which ZIKV crosses the placental barrier at the different stages of gestation. 508 
We used the Nluc-expressing virus to visualize the neutralizing activities and 509 
therapeutic potential of the immune serum #22-1 in mice. As expected, significant 510 
reductions in bioluminescence signal were observed in mice receiving a pre-incubated 511 
virus-immune serum mixture in the early stages of infection. The bioluminescence in 512 
mice peaked at 9 dpi, indicating that pre-incubation before inoculation may not 513 
guarantee the neutralization of all the infectious particles. Nevertheless, these results 514 
provide new evidence for the superior genetic stability of ZIKV-Nluc in vivo compared 515 
with other reporter flaviviruses [19, 24]. As a proof-of-principle experiment, we traced 516 
the infection and clearance of ZIKV-Nluc in A129 mice treated with several doses of 517 
#22-1. The imaging results showed that a significant reduction of bioluminescence was 518 
observed in the mice that received a 9-dose treatment of antiviral serum, indicating that 519 
#22-1 exhibits therapeutic activity similar to that of other reported antibodies [33, 63]. 520 
Previously, bioluminescence imaging has been recommended to predict lethality and 521 
evaluate the efficacy of vaccines and therapeutic strategies in mice [64]. Here, we 522 
demonstrated that the ZIKV-Nluc virus may provide a new means for the development 523 
of antiviral therapeutics and the preclinical evaluation of vaccines.   524 
Despite its merits, this study also contains some limitations. One limitation was 525 
that ZIKV-Nluc exhibited a lower replication efficiency and a lower pathogenicity than 526 
ZIKVwt. Of note, heterologous gene insertions always led to the attenuation of 527 
recombinant RNA viruses [17, 19, 24, 41-43]. Although ZIKV-Nluc was used to 528 
determine the replication, dissemination, and pathogenesis of ZIKV, as well as evaluate 529 
antivirals and vaccines, further studies will be needed to address the issue of attenuation. 530 
The second limitation of this study was the immunocompromised mice that were used. 531 
A129 and AG6 mice have been used previously to mimic aspects of ZIKV infection in 532 
humans. However, due to the lack of key components of antiviral immunity, these 533 
mouse models may not reveal the full range of disease manifestations in humans [11, 534 
65]. Immunologically competent mice treated with IFNAR1-blocking monoclonal 535 
antibody [65] or humanized mouse models may achieve better results in future studies.   536 
In summary, a novel ZIKV reporter virus was established for the in vivo imaging 537 
of ZIKV. This study is the first to investigate the spatio-temporal dynamics of ZIKV 538 
replication, the invasion of immune-sheltered tissues by ZIKV, and the vertical 539 
propagating of ZIKV during pregnancy. In addition to the brain and reproductive tract, 540 
including the testis, uterus, and ovary, the intestine was also demonstrated to be a 541 
potential target of ZIKV dissemination, wherein the ileocecal junction may likely play 542 
a key role in the neuronal dysfunction of ZIKV infection. The non-invasive imaging of 543 
ZIKV-Nluc is a powerful tool for use in the characterisation of the replication, 544 
dissemination, and pathogenesis of ZIKV, as well as for the evaluation of antivirals and 545 
vaccines in vivo for the treatment of ZIKV infection in humans.  546 
 547 
Materials and methods 548 
Ethics statement 549 
All animal experiments were conducted in strict accordance with the institutional 550 
guidelines for animal research and approved by the Administration of Affairs 551 
Concerning Experimental Animals of the People’s Republic of China. All animal 552 
treatments were reviewed and approved in advance by the Ethics Committee of the 553 
Animal House facility of Wuhan Institute of Virology, Chinese Academy of Sciences 554 
(permit no. WIVA07201603). 555 
 556 
Cells and viruses 557 
African green monkey kidney epithelial cells (Vero; CCL-81; ATCC) were cultured in 558 
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, Darmstadt, Germany) 559 
containing 10% fetal bovine serum (FBS) (Life Technology, Australia), 100 U/mL 560 
penicillin, and 100 μg/mL streptomycin maintained in 5% CO2 at 37 °C. The parental 561 
ZIKV was rescued by transfecting Vero cells with the full-length cDNA clone, ZIKV-562 
FL, as previously described [10]. 563 
 564 
Plasmid construction and DNA transfection 565 
To generate the infectious clone of ZIKV-Nluc, ZIKV-FL was used as a backbone to 566 
insert the Nluc reporter gene. As shown in Figure 1A, fragment 1, covering “CMV 567 
promoter-5’UTR-C38”, and fragment 3, covering “C-prM-E187”, were amplified using 568 
ZIKV-FL as a template. Fragment 2, covering (Nluc-2A), was amplified using the 569 
pNL1.1 [Nluc] vector (Promega, Madison, USA) as a template. Fragments 1-3 were 570 
fused together and cloned into ZIKV-FL at the Kpn I and Avr II sites, yielding ZIKV-571 
Nluc-FL. Before transfection, ZIKV-Nluc-FL was verified by restriction enzyme 572 
digestion and complete sequencing. 573 
The full-length cDNA clone ZIKV-Nluc-FL under the control of the CMV 574 
promoter was used to produce infectious viruses. The transfection was performed as 575 
previously described [10]. In brief, Vero cells at 80% confluence in 35 mm culture 576 
dishes were transfected with ZIKV-Nluc-FL by lipofectamine 3000 (Life Technologies). 577 
The supernatant was harvested at 3 days post transfection (dpt), clarified by 578 
centrifugation, and stored at ‒80 °C. 579 
 580 
Immunofluorescence assay (IFA) 581 
The cells infected with ZIKVwt or ZIKV-Nluc were washed once with cold phosphate-582 
buffered saline (PBS) and fixed with cold (‒20 °C) methanol–acetone (1:1) fixation 583 
solution for 12 min at RT. The fixed cells were washed with PBS three times and 584 
incubated with an anti-ZIKV envelope (E) protein MAb (BioFront Technologies, FL, 585 
USA) (diluted 1:200) for 1 h. After washing, the cells were incubated with goat anti-586 
mouse IgG conjugated to FITC (Proteintech, Wuhan, China) (diluted 1:200) at 37 °C 587 
for 60 min. After washing again, the cell nuclei were dyed with Hoechst 33258 at 37 °C 588 
for 10 min. The images were photographed with a NIKON fluorescence microscope 589 
(Tokyo, Japan).  590 
 591 
Plaque assay and immunostaining focus assay 592 
For the double plaque assay, Vero cells at 80% confluence in 6-well plates were 593 
inoculated with 500 μl of 10-fold serial dilutions of viral samples in serum-free DMEM. 594 
After 1.5 h incubation, 3 mL of 0.6% agarose supplemented with 2% FBS was added 595 
into each well. After incubation for 4 days, 3 mL of agarose containing 0.33% neutral 596 
red was added to each well. The plaques were photographed or picked after incubation 597 
for another 24 h. 598 
The immunostaining focus assays were performed as previously described [10]. 599 
In brief, Vero cells in 24-well plates were inoculated with 100 μl of 10-fold serial 600 
dilutions of viral samples for 1.5 h. Then, 1 mL of 1.25% methyl cellulose overlay was 601 
added to each well and the cells were incubated at 37 °C for 4 days. Cells were fixed in 602 
methanol–acetone fixation solution. After washing three times, the cells were incubated 603 
with ZIKV-specific hyperimmune mouse serum. After washing three more times, the 604 
cells were incubated with HRP-conjugated second antibodies. Finally, the viral foci 605 
were visualized by addition of the DAB (3, 3-diaminobenzidine) HRP substrate using 606 
an Enhanced HRP-DAB kit (Tiangen, China), according to the manufacturer’s 607 
instructions. 608 
 609 
Luciferase assay 610 
Vero cells at 80% confluence in 24-well plates were infected with the ZIKV-Nluc virus. 611 
After incubation in 5% CO2 at 37 °C, the cells were lysed with passive lysis buffer at 612 
the indicated time points. Luciferase activities were measured by using the Nano-Glo® 613 
Luciferase Assay System (Promega), according to the manufacturer’s instructions. 614 
 615 
Animal experiments 616 
The strains of mice used in this study were A129 (IFN-α/β receptor deficient), AG6 617 
(IFN-α/β and IFN-γ receptor deficient), and C57BL/6. A129 and AG6 mice were kindly 618 
provided by Gengfu Xiao (Wuhan Institute of Virology, Chinese Academy of Sciences) 619 
and Qibin Leng (Institute Pasteur of Shanghai, Chinese Academy of Sciences), 620 
respectively. C57BL/6 mice were purchased from HuBei Center for Disease Control 621 
(CDC) (Wuhan, China). All mice were bred under specific pathogen-free conditions in 622 
the Animal Resource Center at the Wuhan Institute of Virology, Chinese Academy of 623 
Sciences. 624 
Mice were infected with 1.2 × 105 IFU ZIKV-Nluc/ZIKVwt by intraperitoneal (i.p.) 625 
injection, or 6 ×104 IFU ZIKV-Nluc/ZIKVwt by footpad injection. PBS was injected 626 
into the mock-infected mice by the same route. The clinical course of viral infection 627 
was monitored by survival, weight loss, and disease symptoms. 628 
For tissue localization analysis, 3-4-week-old mice that had received footpad 629 
injections were anesthetized, imaged, and subjected to tissue collection (heart, liver, 630 
spleen, lung, kidney, brain, testes, ovary/uterus, and intestine). All of the tissues were 631 
imaged in vitro, then stored at ‒80 °C for later use. For the study of vertical transmission, 632 
pregnant mice were infected at embryo day 10 (E10) by footpad injection and subjected 633 
to imaging in vivo at the indicated time points. The newborn mice were also examined 634 
by bioluminescence imaging at 1 day after birth. 635 
 636 
Titration of virus from excised tissues 637 
For the measurement of the viral titre, 3-4-week-old AG6 mice that that had received 638 
i.c. injections were anesthetized, imaged, and subjected to tissue collection. At 2, 4, and 639 
5 dpi, the brains of the infected mice were removed, weighed, and homogenized with 640 
zirconia beads in 1 mL of DMEM. Then, the viral titres in the brains were quantified 641 
using immunostaining focus assays.  642 
For the measurement of viral loads, 3-4-week-old AG6 mice that had received 643 
footpad injections were anesthetized, imaged, and subjected to tissue collection. At 1, 644 
3, and 5 dpi, the spleen, kidney, testis, and ileocecal junction of the infected mice were 645 
removed, weighed, and homogenized with zirconia beads in 1 mL of TRIzol reagent. 646 
Next, the viral loads in tissues was quantified using qRT-PCR, as described previously 647 
[10]. Briefly, the total RNA was extracted from various tissues using TRIzol reagent 648 
before being reverse transcribed into cDNA by using the PrimeScript RT reagent kit. A 649 
pair of primers (ZIKV-F: AARTACACATACCARAACAAAGTG and ZIKV-R: 650 
TCCRCTCCCYCTYTGGTCTTG) [66] was used to amplify a conserved sequence of 651 
the NS5 gene. The cycling programme comprised 95 °C for 3 min, 40 cycles of 95 °C 652 
for 10 s, 55 °C for 10 s, and 65 °C for 45 s.  653 
 654 
Bioluminescence imaging 655 
To perform the bioluminescence imaging, the infected mice were shaved in advance 656 
and anaesthetised via the subcutaneous (s.c.) injection of Avertin (150 μl/10 g of 2.5% 657 
solution). The Nano-Glo substrate (Promega) was diluted 1:20 in PBS, and each mouse 658 
was i.p. injected with 100 μl of the mixture. The bioluminescence data were collected 659 
using an IVIS CCD camera system (Caliper Life Science), and further processed in 660 
Living Image (version 4.5) software (Caliper Life Sciences). To analyse the 661 
bioluminescence signals, the ROIs were selected manually in the uniformly scaled 662 
images, and the data were defined as total flux in photons/second. 663 
 664 
Nano-Glo luminescence-based ZIKV neutralization assay 665 
A Nano-Glo luminescence-based ZIKV neutralization assay was developed for the 666 
measurement of the ZIKV-specific neutralizing antibodies, according to a previously 667 
described assay that used plaques as a measurement [10]. Briefly, the serum samples 668 
were two-fold serially diluted, and incubated with 80 IFU of the ZIKV-Nluc virus at 669 
37 °C for 1.5 h. Then, 100 μl of virus–serum mixture was added to Vero cells at 80% 670 
confluence in 24-well plates. After incubation at 37 °C for 1.5 h, the cells were washed 671 
once with PBS, and were then cultured in freshly prepared medium containing 2% FBS. 672 
At 48 hours post infection (hpi), the levels of luciferase activity were measured using 673 
the Nano-Glo® Luciferase Assay System. The 50% neutralization titre (NT50) was 674 
defined as the reciprocal of the highest dilution of each serum sample that resulted in a 675 
50% reduction of the relative light unit relative to the control samples. The traditional 676 
neutralization method, PRNT50, was also performed to ensure the accuracy of the Nano-677 
Glo assay. 678 
 679 
Immunohistochemistry 680 
The immunohistochemistry assays were performed as previously described [5, 10]. In 681 
brief, the tissues were fixed, embedded in paraffin, sectioned at a thickness of 5 μm, 682 
and mounted onto slides. After deparaffinization and antigen retrieval, the sections were 683 
incubated overnight at 4 °C. After washing three times, the sections were incubated 684 
with HRP-conjugated second antibodies and visualized using DAB reagent (Envision 685 
system kit; Dako). The slides were counterstained with haematoxylin and eosin. Images 686 
were captured using a whole-slide digital Pannoramic scanner (3D-Histech, Budapest, 687 
Hungary).  688 
 689 
Statistical analysis 690 
Student’s t-test and analysis of variance (ANOVA) were used to analyse all of the 691 
virologic and immunologic data for significant differences (p < 0.05). The statistical 692 
analyses were performed in IBM SPSS Statistics v18.0 (Chicago, IL, USA). 693 
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